Effectiveness of Ramucirumab Plus Docetaxel for Advanced Non-Small Cell Lung Cancer Patients: a Cohort of 93 Patients

被引：0
|
作者：
Barcelos, Isabella Favato [1 ]
De Marchi, Pedro [1 ]
Aguiar Junior, Pedro Nazareth [1 ]
Montella, Tatiane Caldas [1 ]
Afonso, Nathalia Gimenes [1 ]
Visani, Filipe [1 ]
Negreiros, Izabella Santos [1 ]
De Cerqueira Mathias, Clarissa Maria [1 ]
Paes, Rafael Duarte [1 ]
Dienstmann, Rodrigo [1 ]
Ferreira, Carlos Gil [1 ]
机构：
[1] Oncoclin, Rio De Janeiro, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP.11
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [21] Docetaxel in advanced non-small cell lung cancer
    Wakelee, H
    Ramalingam, S
    Belani, CP
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (01) : 13 - 24
  • [22] Gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer
    Park, SH
    Jeong, SH
    Kyung, SY
    Lim, YH
    An, CH
    Lee, SP
    Park, JW
    Bang, SM
    Cho, EK
    Shin, DB
    Lee, JH
    MEDICAL ONCOLOGY, 2005, 22 (04) : 359 - 366
  • [23] Gemictabine plus carboplatin in patients with advanced non-small cell lung cancer
    Se Hoon Park
    Seong Hwan Jeong
    Sun Young Kyung
    Young-Hee Lim
    Chang Hyeok An
    Sang Pyo Lee
    Jeong Woong Park
    Soo Mee Bang
    Eun Kyung Cho
    Dong Bok Shin
    Jae Hoon Lee
    Medical Oncology, 2005, 22 : 359 - 366
  • [24] Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment
    Saito, Yoshitaka
    Takekuma, Yoh
    Sakakibara-Konishi, Jun
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Sugawara, Mitsuru
    BMC CANCER, 2024, 24 (01)
  • [25] Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
    Wang, Z.
    Han, X.
    Guo, J.
    Zhu, D.
    Zhang, X.
    Tang, X.
    Meng, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1400 - S1400
  • [26] Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
    Paz-Ares, Luis G.
    Perol, Maurice
    Ciuleanu, Tudor-Eliade
    Kowalyszyn, Ruben Dario
    Reck, Martin
    Lewanski, Conrad R.
    Syrigos, Konstantinos
    Arrieta, Oscar
    Prabhash, Kumar
    Park, Keunchil
    Pikiel, Joanna
    Goksel, Tuncay
    Lee, Pablo
    Zimmermann, Anna
    Carter, Gebra Cuyun
    Alexandris, Ekaterine
    Garon, Edward B.
    LUNG CANCER, 2017, 112 : 126 - 133
  • [27] Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer
    Takeda, Koji
    Daga, Haruko
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (12) : 1541 - 1547
  • [28] Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
    Kim, H. R.
    Gridelli, C.
    Kapur, D.
    Tufman, A.
    Felip, E.
    Velcheti, V.
    Kim, Y. J.
    Goetze, T. O.
    Lopez, P. Garrido
    Corre, R.
    Penkov, K.
    Anjum, R.
    Di Pace, B.
    Liu, W.
    Borgovan, T.
    Ledger, D.
    Carver, J.
    Waszak, A.
    Dhar, A.
    Novello, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S109 - S110
  • [29] Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study
    Satoshi Tanizaki
    Kinnosuke Matsumoto
    Akihiro Tamiya
    Yoshihiko Taniguchi
    Yoshinobu Matsuda
    Junji Uchida
    Kiyonobu Ueno
    Hayato Kawachi
    Motohiro Tamiya
    Takafumi Yanase
    Hidekazu Suzuki
    Kyoichi Okishio
    European Journal of Clinical Pharmacology, 2023, 79 : 503 - 511
  • [30] Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study
    Tanizaki, Satoshi
    Matsumoto, Kinnosuke
    Tamiya, Akihiro
    Taniguchi, Yoshihiko
    Matsuda, Yoshinobu
    Uchida, Junji
    Ueno, Kiyonobu
    Kawachi, Hayato
    Tamiya, Motohiro
    Yanase, Takafumi
    Suzuki, Hidekazu
    Okishio, Kyoichi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (04) : 503 - 511
12345